Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression
(2007) In Journal of Proteome Research 6(2). p.75-869- Abstract
Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent... (More)
Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.
(Less)
- author
- Puchades, Maja ; Nilsson, Carol L LU ; Emmett, Mark R ; Aldape, Kenneth D ; Ji, Yongjie ; Lang, Frederick ; Liu, Ta-Jen and Conrad, Charles A.
- publishing date
- 2007-02
- type
- Contribution to journal
- publication status
- published
- keywords
- Animals, Antineoplastic Agents, Blotting, Western, Cell Division, Cell Line, Tumor, Cell Survival, Electrophoresis, Gel, Two-Dimensional, Galectin 1, Genetic Therapy, Glioblastoma, Humans, Mass Spectrometry, Neoplasm Transplantation, Proteomics, Transplantation, Heterologous, Tumor Suppressor Protein p53, Journal Article, Research Support, Non-U.S. Gov't
- in
- Journal of Proteome Research
- volume
- 6
- issue
- 2
- pages
- 7 pages
- publisher
- The American Chemical Society (ACS)
- external identifiers
-
- scopus:33847399649
- pmid:17269744
- ISSN
- 1535-3893
- DOI
- 10.1021/pr060302l
- language
- English
- LU publication?
- no
- id
- ba4ba3a9-82c5-4aa6-822d-9497456414a9
- date added to LUP
- 2017-05-16 10:33:14
- date last changed
- 2024-04-14 10:47:26
@article{ba4ba3a9-82c5-4aa6-822d-9497456414a9,
abstract = {{<p>Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.</p>}},
author = {{Puchades, Maja and Nilsson, Carol L and Emmett, Mark R and Aldape, Kenneth D and Ji, Yongjie and Lang, Frederick and Liu, Ta-Jen and Conrad, Charles A.}},
issn = {{1535-3893}},
keywords = {{Animals; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Survival; Electrophoresis, Gel, Two-Dimensional; Galectin 1; Genetic Therapy; Glioblastoma; Humans; Mass Spectrometry; Neoplasm Transplantation; Proteomics; Transplantation, Heterologous; Tumor Suppressor Protein p53; Journal Article; Research Support, Non-U.S. Gov't}},
language = {{eng}},
number = {{2}},
pages = {{75--869}},
publisher = {{The American Chemical Society (ACS)}},
series = {{Journal of Proteome Research}},
title = {{Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression}},
url = {{http://dx.doi.org/10.1021/pr060302l}},
doi = {{10.1021/pr060302l}},
volume = {{6}},
year = {{2007}},
}